Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R21)

The summary for the Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R21) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Pancreatic Development and Regeneration: Toward Cellular Therapies for Diabetes (R21): -The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications to understand how endogenous pancreatic beta cells are made by studying pancreatic development, with the goal of making pancreatic islets in culture, to explore the potential of animal or human stem/progenitor cells (embryonic or adult; if human embryonic, only NIH approved human embryonic stem cell lines may be used) as a source for making pancreatic islets, and to determine the basic mechanisms underlying beta cell regeneration in the adult as a basis for producing new cellular therapies for diabetes. This funding opportunity announcement (FOA) is intended to stimulate the application of advances made in developmental biology, stem cell biology, and diabetes to develop new strategies for diabetes therapy, either through cell replacement or regeneration. This FOA is intended to intensify investigator-initiated research, to attract new investigators to the field, and to encourage interdisciplinary approaches to research in this area. -This FOA will utilize the Exploratory/Developmental (R21) grant mechanism and runs in parallel with a FOA of identical scientific scope, PA-06-271, that solicits applications under the R01 grant mechanism. -Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received. -The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year. -Eligible organizations: For profit and non-profit organizations, including public or private institutions, units of state and local governments, eligible agencies of the federal government, domestic or foreign institutions/organizations, faith-based or community-based organizations, and units of State and Local Tribal governments. -Eligible Project Directors/Principal Investigators (PD/PIs): Any individual with the skill, knowledge and resources necessary to carry out the proposed research. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH programs. -Applicants may submit more than one application, provided they are scientifically distinct.